Who is sponsoring NCT03931083?

NCT03931083 is sponsored by University of Bern.

What drugs are being tested in NCT03931083?

Interventions in NCT03931083: Screening for CIN2+/HSIL.

What condition does NCT03931083 study?

NCT03931083 studies Uterine Cervical Neoplasms, HIV/AIDS.

Is NCT03931083 still recruiting?

NCT03931083 is currently status unknown. Last updated 3 November 2020.

Last reviewed 2020-11-03 · How we verify

NCT03931083

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Screening Test Accuracy of Gynocular™, HR-HPV Testing, VIA for Detection of Cervical Neoplastic Lesions, in Women Living With HIV

Status unknown Last updated 3 November 2020

What this trial tests

trial testing Screening for CIN2+/HSIL in Uterine Cervical Neoplasms in 450 participants. Status unknown.

Timeline

8 May 2019

Primary endpoint
1 January 2021

1 December 2022

Quick facts

Lead sponsor	University of Bern
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	450
Start date	8 May 2019
Primary completion	1 January 2021
Estimated completion	1 December 2022
Sites	1 location across Zambia

Drugs / interventions tested

Screening for CIN2+/HSIL

Conditions studied

Uterine Cervical Neoplasms — all drugs for Uterine Cervical Neoplasms →
HIV/AIDS — all drugs for HIV/AIDS →

Sponsor

University of Bern

Who can join

Adults 18 to 65, female only, with Uterine Cervical Neoplasms or HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cervical cancer in HIV-positive women is largely preventable through regular screening. The World Health Organization (WHO) recommends cervical screening for HIV-positive women every three years. Currently the least costly method for screening and the most viable option for many countries is visual inspection after application of acetic acid (VIA). Alternative testing methods are HPV testing and assessment with a portable magnification device. The investigators plan to assess and compare the screening test accuracy of these screening tests in women living with HIV. All women will receive histopathology reference standard.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers.
Lin LL, Lakomy DS, Chiao EY, Strother RM, et al · · 2020 · cited 19× · PMID 32697667 · DOI 10.1200/go.20.00153
Screening test accuracy of portable devices that can be used to perform colposcopy for detecting CIN2+ in low- and middle-income countries: a systematic review and meta-analysis.
Taghavi K, Rohner E, Basu P, Low N, et al · · 2020 · cited 13× · PMID 33198721 · DOI 10.1186/s12905-020-01121-3
Screening test accuracy to improve detection of precancerous lesions of the cervix in women living with HIV: a study protocol.
Taghavi K, Moono M, Mwanahamuntu M, Basu P, et al · · 2020 · cited 6× · PMID 33371015 · DOI 10.1136/bmjopen-2020-037955
Accuracy of screening tests for cervical precancer in women living with HIV in low-resource settings: a paired prospective study in Lusaka, Zambia.
Taghavi K, Moono M, Mwanahamuntu M, Roumet M, et al · · 2024 · cited 3× · PMID 39886160 · DOI 10.1136/bmjonc-2023-000111
Accuracy of screening tests for cervical pre-cancer in women living with HIV in low-resource settings: a paired prospective study in Lusaka, Zambia
Taghavi K, Moono M, Mwanahamuntu M, Roumet M, et al · · 2023 · DOI 10.1101/2023.05.31.23290779

Verify or expand the search:

Other recruiting trials for Uterine Cervical Neoplasms

Currently open trials in the same condition.

NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting
NCT07011836 — Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women · NA · recruiting
NCT06815939 — Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer · NA · recruiting
NCT06558682 — Neoadjuvant Therapy in Cervical Cancer · NA · recruiting
NCT06509724 — Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy · Phase 3 · recruiting

Other University of Bern trials

Trials by the same sponsor.

NCT05940662 — Cost Effectiveness of Various Implant Placement Protocols in the Esthetic Zone · Phase 4 · suspended
NCT02919163 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7) · NA · not yet recruiting
NCT02919189 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7) · NA · not yet recruiting
NCT04817592 — Characterization of the Corneal Biomechanics of Patients Treated by Corneal Lenticule Extraction for Advanced Refractive · not yet recruiting
NCT06806150 — The INSPIRE Study: INvestigation of Swiss Physicians Inner-life, Resilience, and Emotions · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03931083 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Bern
Last refreshed: 3 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03931083.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing